What is PATH EX?
PATH EX is at the forefront of developing investigational extracorporeal blood cleansing devices designed for the diagnosis and treatment of sepsis. Their proprietary technology focuses on the selective removal of pathogens and endotoxins directly from the bloodstream. Studies have demonstrated significant reductions in bacterial concentrations, positioning PATH EX's innovations as a potentially transformative solution for critical care settings and infectious disease management, particularly in the immediate treatment of bacteremia. The company's work holds profound implications for improving patient outcomes in healthcare environments where rapid intervention is paramount.
How much funding has PATH EX raised?
PATH EX has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2025): $5M with participation from IAG Capital Partners, TMC Ventures, and Fitz Gate Ventures
Key Investors in PATH EX
IAG Capital Partners
IAG Capital Partners is a venture capital firm specializing in leading investment rounds from seed to Series C, operating from Charleston, SC, and London, UK. They focus on providing financial support to innovative companies at various stages of their development.
TMC Ventures
TMC Ventures specializes in carefully selected, evidence-based supplements for various health concerns, emphasizing ethical practices and customer value. They aim to support clients seeking reliable nutritional supplements for improved health and wellness.
Fitz Gate Ventures
Fitz Gate Ventures is an early-stage venture capital firm that invests across the U.S. with an emphasis on deeptech startups, leveraging its 'Friends of Fitz' community for strategic advantages.
What's next for PATH EX?
The substantial enterprise-level funding signifies a pivotal moment for PATH EX, likely enabling the company to accelerate its research and development pipeline, scale manufacturing capabilities, and pursue regulatory approvals. This capital infusion is expected to fuel the advancement of their investigational blood cleansing devices, potentially bringing them closer to widespread clinical adoption. The strategic investment suggests a focus on expanding market reach and solidifying their position in the critical care and infectious disease management sectors. PATH EX is poised to make significant strides in addressing the urgent need for effective sepsis treatments.
See full PATH EX company page
